Skip to main content
Back
Watch Compare

LIPELLA PHARMACEUTICALS INC.

Data quality: 100%
LIPO
OTC Manufacturing Chemicals
$0.04
▲ $0.01 (59.09%)
Mkt Cap: 161,729.0
Price
$0.04
Mkt Cap
161,729.0
Day Range
$0.01 — $0.02
52-Week Range
$0.01 — $3.17
Volume
54
Open $0.01
50D / 200D Avg
$0.16
78.00% below
50D / 200D Avg
$0.44
92.10% below

Quick Summary

Key Takeaways

Negative free cash flow of -4.78 M
Capital efficient — spends only 0.00% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)19.29%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-252.04%
Below sector avg (-51.02%)
ROIC-182.62%
Net Margin-1367.37%
Op. Margin-1387.94%

Safety

Debt / Equity
N/A
Current Ratio3.24
Interest CoverageN/A

Valuation

PE (TTM)
-0.03
Above sector avg (-1.98)
P/B Ratio0.11
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E 0.0 -2.0
P/B 0.1 5.1
ROE % -252.0 -51.0
Net Margin % -1367.4 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 19.29% Revenue Growth (3Y) 70.66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 389,783.0 Net Income (TTM) -5.33 M
ROE -252.04% ROA -175.61%
Gross Margin N/A Operating Margin -1387.94%
Net Margin -1367.37% Free Cash Flow (TTM) -4.78 M
ROIC -182.62% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.24
Interest Coverage N/A Asset Turnover 0.13
Working Capital 1.44 M Tangible Book Value 1.49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.03 Forward P/E N/A
P/B Ratio 0.11 P/S Ratio 0.41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -2952.92%
Market Cap 161,729.0 Enterprise Value -1.69 M
Per Share
EPS (Diluted TTM) -2.26 Revenue / Share 0.08
FCF / Share -1.03 OCF / Share -1.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.00% FCF Conversion 89.61%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 536,357.0 449,617.0 184,156.0
Net Income -5.02 M -4.62 M -2.60 M
EPS (Diluted) -4.79 -0.77 -0.64
Gross Profit — — —
Operating Income -5.08 M -4.75 M -2.59 M
EBITDA — — —
R&D Expenses 3.61 M 3.04 M 2.55 M
SG&A Expenses — — —
D&A 2,886.0 1,685.0 —
Interest Expense 10,848.0 10,848.0 9,612.0
Income Tax — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 2.67 M 3.58 M 5.95 M
Total Liabilities 754,417.0 432,726.0 1.27 M
Shareholders' Equity 1.92 M 3.14 M 4.68 M
Total Debt — — —
Cash & Equivalents 2.18 M 3.29 M 5.12 M
Current Assets 2.62 M 3.43 M 5.80 M
Current Liabilities 754,417.0 385,355.0 1.18 M